Long-term debt · 2019–2025

Akebia Therapeutics long-term debt

$48.3M+24.7% · FY2025

Akebia Therapeutics (AKBA) reported $48.3M in long-term debt for fiscal 2025, +24.7% year on year.

$75.8M2019$96.4M2020$02021$34.1M2022$17.2M2023$38.7M2024$48.3M2025
Akebia Therapeutics — Long-term debt, 2019–2025
Fiscal yearLong-term debtChangeFiling
FY20252025-12-31$48.3M+24.7%Open →
FY20242024-12-31$38.7M+125.2%Open →
FY20232023-12-31$17.2M−49.6%Open →
FY20222022-12-31$34.1M+$34.1MOpen →
FY20212021-12-31$0−100.0%Open →
FY20202020-12-31$96.4M+27.1%Open →
FY20192019-12-31$75.8M—Open →

Long-term debt — Long-term debt is borrowing due more than a year out. A large figure is normal for capital-intensive businesses and says nothing on its own about financial health.

Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2019–2025 compound annual growth −7.3%

Long-term debt at companies of similar size

Full ranking by long-term debt →

Cite this page

Ready-made references for the figures on this page, as published on September 25, 2026.

Wikipedia

{{cite web |title=Akebia Therapeutics long-term debt |url=https://companiesranked.com/en/company/akebia-therapeutics/long-term-debt |website=CompaniesRanked |date=2026-09-25 |language=en}}

APA 7

CompaniesRanked. (September 25, 2026). Akebia Therapeutics long-term debt. CompaniesRanked. https://companiesranked.com/en/company/akebia-therapeutics/long-term-debt

BibTeX

@misc{companiesranked-en-company-akebia-therapeutics-long-term-debt-2026,
  author       = {{CompaniesRanked}},
  title        = {{Akebia Therapeutics long-term debt}},
  year         = {2026},
  howpublished = {\url{https://companiesranked.com/en/company/akebia-therapeutics/long-term-debt}},
  note         = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
  urldate      = {2026-09-25}
}

The filing itself

The numbers above are read from this document: 10-Q · 0001517022-26-000051 · August 5, 2026

{{cite web |title=Akebia Therapeutics long-term debt — 10-Q (0001517022-26-000051) |url=https://www.sec.gov/Archives/edgar/data/1517022/000151702226000051/akba-20260630.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-08-05}}

The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.

← Akebia Therapeutics overview